Navigation Links
Corgenix to Host Conference Call to Discuss Fiscal 2008 Results
Date:9/15/2008

DENVER, Sept. 15 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, September 25, 2008, at 4:00 PM EDT to discuss the Company's financial and operating performance for its fiscal year ended June 30, 2008, and the status of the Company's product development and marketing activities.

Corgenix invites all those interested in hearing management's discussion of the annual results to join the call by dialing:

US attendees: (800) 894-5910

International attendees: +1 785 424 1052

Conference code is: CORGENIX

A question-and-answer session will follow the presentation by Corgenix management.

A replay will be available for 30 days following the call by dialing (800) 374-0934 for US participants and +1 402 220 0680 for international participants.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin non-responsiveness. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at http://www.corgenix.com.


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Corgenix Expands Scientific Advisory Board
2. Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco
3. Corgenix to Host Conference Call to Discuss Third Quarter Fiscal 2008 Results
4. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
5. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
6. Corgenix Signs Technology Licensing Agreement With Japanese Government
7. MannKind to Present at the UBS Global Life Sciences Conference
8. Insmed to Present at Biosimilars 2008 Conference
9. Modigene to Present at the UBS Global Life Sciences Conference
10. Vical to Present at UBS Global Life Sciences Conference
11. Stryker to Host Conference Call on October 16, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... optimized Erk inhibitor molecule for development, thus achieving ... new class of potential cancer therapies. ... for therapeutic intervention in cancer. Recently approved compounds ... B-Raf and Mek inhibitors. Erk inhibitors may be ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead Levee Design Engineering Manager ... Orange County, Texas area from future storm surge flooding, such as occurred in Hurricane ... levee alignment alternatives for providing protection, Costello also balanced socio-economic and environmental needs ...
(Date:7/28/2015)... 29, 2015 A ... rapidly developing and commercialising innovative medicines to transform ... Highly experienced management team; blue chip ... Mereo BioPharma Group Ltd ("Mereo"), a recently-formed speciality ... c. £76.5m), gross, from blue chip institutional investors and ...
(Date:7/28/2015)... YORK , July 28, 2015 People ... by hearing aids achieved significant and sometimes profound improvements ... cochlear implant devices, according to a new multicenter study ... In the study, described online ahead of print in ... medical centers and private clinics in the ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3
... Q4/07 Review Issued by Scimitar Equity Research, Inc., ... Inc.,(Scimitar) issues a review of Neurobiological Technologies, Inc. ... of Purpose:,VIPRINEX(TM) Could Restore Stroke Patients to Fuller ... NTII,s Achievement". This review is available at ...
... Merger, IRVINE, California, September 19 ... orthobiologics company, today announced that,Institutional Shareholder Services, ... the merger of IsoTis and Integra,LifeSciences Holdings ... For every M&A analysis, ISS reviews publicly ...
... new speakers will,grace the faculty of the "Pharma ... two weeks in New Jersey. The conference is,the ... Market,Forecasting executives; 200 from the top 25 companies ... Competition has never been fiercer to,launch successful products ...
Cached Biology Technology:Neurobiological Technologies, Inc. (Nasdaq: NTIID) 2IsoTis - Integra Merger 2IsoTis - Integra Merger 3IsoTis - Integra Merger 4IsoTis - Integra Merger 5New Competitive Intelligence Speakers Spark Interest in Pharmaceutical Conference on October 1-2 in NJ 2
(Date:6/25/2015)... CITY , June 25, 2015  Imagine a ... steps toward a healthier, happier life. That,s exactly what ... designed to do. The cutting-edge, portable health program provides ... real-life solutions to help improve your lifestyle and nutrition. ... awards dinner and gala Wednesday night, USANA,s THA was ...
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... Despite current beliefs, sugar intake is not directly associated ... study in Gastroenterology , the official journal of ... progression of this serious form of liver disease. ... overweight men to compare the effects of high intakes ...
... found an association between lower socioeconomic status during childhood ... protein complexes at the end of chromosomes, that ultimately ... Published in Brain, Behavior and Immunity ... parents of lower socioeconomic status have shorter telomeres as ...
... disappearedwere home to dozens of species of grasses that could ... of flowers, and herds of roaming bison. For ... of Colorado Boulder has gotten a peek at another vitally ... tallgrass prairie home: the diverse assortment of microbes that thrived ...
Cached Biology News:Sugar intake is not directly related to liver disease 2Children of lower socioeconomic status grow up more susceptible to catching colds, Carnegie Mellon researchers find 2CU-Boulder-led team gets first look at diverse life below rare tallgrass prairies 2
... Adding an exciting new chapter ... GC leadership, Agilents 7890A GC ... to take your lab to ... and GC/MS performance, including advanced ...
... Pan-Caspase In Situ Assay Kit, Fluorescein is ... caspases in cells undergoing apoptosis. The kit ... use in diagnostic or therapeutic procedures. CHEMICON®s ... a novel approach to detect active caspases. ...
... concentrated jetSI 10 nM is available for ... brain as described in: Z. Hassani, G.-F. ... J.-P. Behr, and B.-A. Demeneix. Lipid-mediated siRNA ... the mouse brain at picomolar levels. J. ...
... Tissue Staining Kits are intended for localization ... histological and cytological specimens. These kits may ... by either R&D Systems or by other ... formation of the Avidin-Biotin Complex (ABC) with ...
Biology Products: